(Q38170498)

30 August 2017

title

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma (English)

1 reference

30 August 2017

Markus Chmielewski

1

1 reference

30 August 2017

Andreas A Hombach

series ordinal

2

1 reference

30 August 2017

Hinrich Abken

series ordinal

3

1 reference

30 August 2017

publication date

1 January 2014

1 reference

30 August 2017

published in

Immunological Reviews

1 reference

30 August 2017

volume

257

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

83-90

1 reference

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

30 August 2017

cites work

1 reference

The T-body approach: redirecting T cells with antibody specificity

21 January 2018

1 reference

Building better chimeric antigen receptors for adoptive T cell therapy

21 January 2018

1 reference

Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling

21 January 2018

1 reference

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

21 January 2018

1 reference

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophils

21 January 2018

1 reference

Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment

21 January 2018

1 reference

Cancer despite immunosurveillance: immunoselection and immunosubversion

21 January 2018

1 reference

T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity.

21 January 2018

1 reference

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells

21 January 2018

1 reference

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression

21 January 2018

1 reference

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

21 January 2018

1 reference

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts

21 January 2018

1 reference

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.

21 January 2018

1 reference

The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses

21 January 2018

1 reference

The central role of CD4(+) T cells in the antitumor immune response

21 January 2018

1 reference

Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages

21 January 2018

1 reference

Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function

21 January 2018

1 reference

T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal

21 January 2018

1 reference

Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis

21 January 2018

1 reference

Interleukin-12 and the regulation of innate resistance and adaptive immunity

21 January 2018

1 reference

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

The toxicology of interleukin-12: a review

21 January 2018

1 reference

IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments

21 January 2018

1 reference

Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study

21 January 2018

1 reference

Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study

21 January 2018

1 reference

Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma

21 January 2018

1 reference

IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46.

21 January 2018

1 reference

Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12.

21 January 2018

1 reference

Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment

21 January 2018

1 reference

The anti-tumor effect of interleukin-12 is enhanced by mild (fever-range) thermal therapy.

21 January 2018

1 reference

A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells

21 January 2018

1 reference

IL-12 plays a significant role in the apoptosis of human T cells in the absence of antigenic stimulation

21 January 2018

1 reference

Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12.

21 January 2018

1 reference

Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice

21 January 2018

1 reference

Bystander elimination of antigen loss variants in established tumors

21 January 2018

1 reference

Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice.

21 January 2018

1 reference

A self-inactivating retrovector incorporating the IL-2 promoter for activation-induced transgene expression in genetically engineered T-cells

21 January 2018

1 reference

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

21 January 2018

1 reference

The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells

21 January 2018

1 reference

IL-12 can alleviate Th17-mediated allergic lung inflammation through induction of pulmonary IL-10 expression

21 January 2018

1 reference

New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions

21 January 2018

1 reference

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

21 January 2018

1 reference

IL-23 promotes tumour incidence and growth

21 January 2018

1 reference

Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity

21 January 2018

1 reference

Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation

21 January 2018

1 reference

Nitric oxide short-circuits interleukin-12-mediated tumor regression.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/IMR.12125

1 reference

30 August 2017

1 reference